Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
HRTXHeron Therapeutics(HRTX) Zacks Investment Research·2024-05-07 22:36

Heron Therapeutics (HRTX) reported 34.67millioninrevenueforthequarterendedMarch2024,representingayear−over−yearincreaseof17.134.67 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 17.1%. EPS of -0.02 for the same period compares to -0.27ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof0.27 a year ago. The reported revenue compares to the Zacks Consensus Estimate of 32.5 million, representing a surprise of +6.68%. The company delivered an EPS surprise of +75.00%, with the consensus EPS estimate being -$0.08. While investors closely watch year-over-year changes in headline numbers -- revenue and earn ...